Ismail Tavsu1, Tugba Gursoy2, Sukriye Dirman3, Nazan Erbil1, Fahri Ovali4. 1. Pediatrician, Department of Pediatrics, Zeynep Kamil Maternity and Children's Research and Training Hospital, Istanbul, Turkey. 2. Associate Professor of Neonatology, Neonatal Intensive Care Unit, Zeynep Kamil Maternity and Children's Research and Training Hospital, Istanbul, Turkey. 3. Child Development Specalist, Department of Pediatrics, Zeynep Kamil Maternity and Children's Research and Training Hospital, Istanbul, Turkey. 4. Professor of Neonatology, Neonatal Intensive Care Unit, Zeynep Kamil Maternity and Children's Research and Training Hospital, Istanbul, Turkey.
Abstract
AIM: To evaluate the rehospitalization rates of premature infants who receivedpalivizumab prophylaxis and its influence on the growth and development of these infants. METHODS:Infants with a gestational age of less than 32 weeks were randomized to receive prophylaxis with palivizumab (study group) or nothing (control group). Nasal swab samples were obtained monthly in all cases and also in case of infection and hospitalization. At the corrected age of 18 months Guide for Monitoring Child Development (GMCD) was administered to all patients and anthropometric indices were evaluated. RESULTS: The study was completed with 39 infants in the study group and 40 infants in the control group. Incidence of hospitalization due to respiratory syncitial virus (RSV) was found to be significantly lower in the study group both at the year of prophylaxis and in the following year (p = 0.001, odds ratio 1.32 [1.11-1.57]). There were no significant differences in terms of anthropometric indices or GMCD tests between the groups at the corrected age of 18 months. CONCLUSION:Palivizumab reduced the incidence of lower respiratory tract infections and hospitalizations due to RSV both in the year of prophylaxis and in the following year. However, this decrease did not have any impact on the development of infants. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
RCT Entities:
AIM: To evaluate the rehospitalization rates of premature infants who received palivizumab prophylaxis and its influence on the growth and development of these infants. METHODS:Infants with a gestational age of less than 32 weeks were randomized to receive prophylaxis with palivizumab (study group) or nothing (control group). Nasal swab samples were obtained monthly in all cases and also in case of infection and hospitalization. At the corrected age of 18 months Guide for Monitoring Child Development (GMCD) was administered to all patients and anthropometric indices were evaluated. RESULTS: The study was completed with 39 infants in the study group and 40 infants in the control group. Incidence of hospitalization due to respiratory syncitial virus (RSV) was found to be significantly lower in the study group both at the year of prophylaxis and in the following year (p = 0.001, odds ratio 1.32 [1.11-1.57]). There were no significant differences in terms of anthropometric indices or GMCD tests between the groups at the corrected age of 18 months. CONCLUSION:Palivizumab reduced the incidence of lower respiratory tract infections and hospitalizations due to RSV both in the year of prophylaxis and in the following year. However, this decrease did not have any impact on the development of infants. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Authors: Adel S Alharbi; Mansour Alqwaiee; Mohammed Y Al-Hindi; Rafat Mosalli; Abdullah Al-Shamrani; Saleh Alharbi; Abdullah Yousef; Amal Al Aidaroos; Turki Alahmadi; Aisha Alshammary; Abeer Miqdad; Yazan Said; Abdulrahman Alnemri Journal: Ann Thorac Med Date: 2018 Jul-Sep Impact factor: 2.219